Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Necrosis in breast cancer patients with skin metastases receiving bevacizumab-based therapy.

Cottu PH, Fourchotte V, Vincent-Salomon A, Kriegel I, Fromantin I.

J Wound Care. 2011 Sep;20(9):403-4, 406, 408 passim.

PMID:
22068139
2.

Impaired wound healing and bilateral mastectomy flap necrosis in a patient with locally advanced breast cancer after neoadjuvant Paclitaxel with bevacizumab.

Lazzati V, Zygoń J, Lohsiriwat V, Veronesi P, Petit JY.

Aesthetic Plast Surg. 2010 Dec;34(6):796-7. doi: 10.1007/s00266-010-9535-5. No abstract available.

PMID:
20567970
3.

Hypertension as a predictive marker for bevacizumab in metastatic breast cancer: results from a retrospective matched-pair analysis.

Gampenrieder SP, Romeder F, Muß C, Pircher M, Ressler S, Rinnerthaler G, Bartsch R, Sattlberger C, Mlineritsch B, Greil R.

Anticancer Res. 2014 Jan;34(1):227-33.

PMID:
24403467
4.

[A case report-bleeding from the ulcer of wound for mastectomy after postoperative chemotherapy with bevacizumab for Sigmoid colon cancer].

Tsumuraya M, Fujita M, Muroi H, Sugawara A, Tsubaki M, Kato H.

Gan To Kagaku Ryoho. 2011 Nov;38(11):1869-71. Japanese.

PMID:
22083200
5.

Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer.

Guarneri V, Miles D, Robert N, Diéras V, Glaspy J, Smith I, Thomssen C, Biganzoli L, Taran T, Conte P.

Breast Cancer Res Treat. 2010 Jul;122(1):181-8. doi: 10.1007/s10549-010-0866-3. Epub 2010 Apr 2.

PMID:
20361252
6.

[Surgical management of bevacizumab-associated peritonitis due to perforation].

Kube R, Meyer F, Bien N, Schmidt C, Mroczkowski P, Dalicho S, Lippert H.

Zentralbl Chir. 2009 Sep;134(5):462-7. doi: 10.1055/s-0028-1098701. Epub 2009 Sep 15. German.

PMID:
19757347
7.

Bevacizumab and wound-healing complications: mechanisms of action, clinical evidence, and management recommendations for the plastic surgeon.

Sharma K, Marcus JR.

Ann Plast Surg. 2013 Oct;71(4):434-40. doi: 10.1097/SAP.0b013e31824e5e57. Review.

PMID:
22868316
8.

Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab.

Scappaticci FA, Fehrenbacher L, Cartwright T, Hainsworth JD, Heim W, Berlin J, Kabbinavar F, Novotny W, Sarkar S, Hurwitz H.

J Surg Oncol. 2005 Sep 1;91(3):173-80.

PMID:
16118771
9.

Evaluation of acute locoregional toxicity in patients with breast cancer treated with adjuvant radiotherapy in combination with bevacizumab.

Goyal S, Rao MS, Khan A, Huzzy L, Green C, Haffty BG.

Int J Radiat Oncol Biol Phys. 2011 Feb 1;79(2):408-13. doi: 10.1016/j.ijrobp.2009.11.021. Epub 2010 May 6.

PMID:
20452134
10.

Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer.

von Minckwitz G, Eidtmann H, Rezai M, Fasching PA, Tesch H, Eggemann H, Schrader I, Kittel K, Hanusch C, Kreienberg R, Solbach C, Gerber B, Jackisch C, Kunz G, Blohmer JU, Huober J, Hauschild M, Fehm T, Müller BM, Denkert C, Loibl S, Nekljudova V, Untch M; German Breast Group; Arbeitsgemeinschaft Gynäkologische Onkologie–Breast Study Groups.

N Engl J Med. 2012 Jan 26;366(4):299-309. doi: 10.1056/NEJMoa1111065.

11.

Wound healing and catheter thrombosis after implantable venous access device placement in 266 breast cancers treated with bevacizumab therapy.

Kriegel I, Cottu PH, Fourchotte V, Sanchez S, Fromantin I, Kirov K, Guillaume A, Pelloquin A, Esteve M, Salmon RJ.

Anticancer Drugs. 2011 Nov;22(10):1020-3. doi: 10.1097/CAD.0b013e328349c7bb.

PMID:
21970853
12.

A review on bevacizumab and surgical wound healing: an important warning to all surgeons.

Gordon CR, Rojavin Y, Patel M, Zins JE, Grana G, Kann B, Simons R, Atabek U.

Ann Plast Surg. 2009 Jun;62(6):707-9. doi: 10.1097/SAP.0b013e3181828141.

PMID:
19461291
13.

Safety of bevacizumab in metastatic breast cancer patients undergoing surgery.

Cortés J, Caralt M, Delaloge S, Cortes-Funes H, Pierga JY, Pritchard KI, Bollag DT, Miles DW.

Eur J Cancer. 2012 Mar;48(4):475-81. doi: 10.1016/j.ejca.2011.11.021. Epub 2011 Dec 22.

PMID:
22196033
14.

Use of S-100B to evaluate therapy effects during bevacizumab induction treatment in AJCC stage III melanoma.

Kruijff S, Bastiaannet E, Brouwers AH, Nagengast WB, Speijers MJ, Suurmeijer AJ, Hospers GA, Hoekstra HJ.

Ann Surg Oncol. 2012 Feb;19(2):620-6. doi: 10.1245/s10434-011-2027-2. Epub 2011 Aug 23.

15.

Bevacizumab-associated hyperlipoproteinemia type IIb in a patient with advanced invasive-ductal breast cancer.

Joerger M, Riesen WF, Thürlimann B.

J Oncol Pharm Pract. 2011 Sep;17(3):292-4. doi: 10.1177/1078155210378912. Epub 2010 Jul 28.

PMID:
20667851
16.

Bevacizumab safety in patients with central nervous system metastases.

Besse B, Lasserre SF, Compton P, Huang J, Augustus S, Rohr UP.

Clin Cancer Res. 2010 Jan 1;16(1):269-78. doi: 10.1158/1078-0432.CCR-09-2439. Epub 2009 Dec 22.

17.

Safety of bevacizumab in patients with metastatic breast cancer.

Hamilton EP, Blackwell KL.

Oncology. 2011;80(5-6):314-25. doi: 10.1159/000328757. Epub 2011 Jul 19. Review.

PMID:
21778772
18.

"Spontaneous," delayed colon and rectal anastomotic complications associated with bevacizumab therapy.

August DA, Serrano D, Poplin E.

J Surg Oncol. 2008 Feb 1;97(2):180-5.

PMID:
18095268
19.

Unexpected late radiation neurotoxicity following bevacizumab use: a case series.

Kelly PJ, Dinkin MJ, Drappatz J, O'Regan KN, Weiss SE.

J Neurooncol. 2011 May;102(3):485-90. doi: 10.1007/s11060-010-0336-0. Epub 2010 Aug 1.

PMID:
20680396
20.

Safety and tolerability of first-line bevacizumab in metastatic colorectal cancer.

Akun E, Okutur K, Seber S, Korkmaz T, Aydin K, Bozkurt M, Namal E, Hasbal B, Tecimer C, Demir G.

J BUON. 2012 Oct-Dec;17(4):669-76.

PMID:
23335523
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk